Logo of Nova Eye Medical (ASX:EYE)Latest Nova Eye Medical (ASX:EYE) News

Page 1
Page 1 of 2

Nova Eye Medical reaches positive EBITDA as sales growth accelerates

Nova Eye Medical delivered 30% year-on-year sales growth in the September quarter, alongside positive operating cash flow and EBITDA. The company confirmed FY27 guidance, but is still seeking to replace a related-party funding facility carrying 15% interest.
Victor Sage
27 Oct 2026

Healthcare Wrap - Week 19 (4 May -> 8 May) 2026

Big capital raisings, fresh trial data and a few boardroom shocks shaped healthcare trading this week. The biggest moves came from companies either fixing the balance sheet, explaining heavy selling, or pushing key drugs and devices closer to market.
Logan Eniac
9 May 2026

Nova Eye Medical Lifts FY26 Sales Forecast After US April Sales Record

Nova Eye Medical has smashed its US sales record in April 2026, prompting an upgrade to its FY26 sales guidance and marking a milestone with positive operational EBITDA.
Ada Torres
5 May 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026

Nova Eye Medical Narrows EBITDA Loss with 23% Sales Growth and New US Product Feature

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.
Ada Torres
29 Apr 2026

Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.
Logan Eniac
31 Jan 2026

Nova Eye Medical Surges with Record US$6.1M Quarter and 24% Annual Growth

Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.
Ada Torres
29 Jan 2026

Market Wrap - Week 3 (12 Jan -> 16 Jan) 2026

A few stocks did the heavy lifting this week, with one biotech exploding higher and a gas name collapsing on the other side of the ledger. Big moves came from capital raises, regulator decisions, and drill results that investors treated as near-term value, not distant promises.
Logan Eniac
18 Jan 2026

Nova Eye Medical Surges with Record US$6.1M Quarter, US Market Leads Growth

Nova Eye Medical has reported a record US$6.1 million in sales for the December 2025 quarter, driven by strong US demand and a 24% annual growth rate that outpaces the industry.
Ada Torres
12 Jan 2026

Nova Eye Medical’s Q1 Revenue Climbs 20%, Eyes Breakeven by Mid-2026

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.
Ada Torres
5 Nov 2025

Nova Eye Medical’s Sales Surge 32%, Eyes China Market with New Approval

Nova Eye Medical reported a robust 32% increase in global sales excluding China for Q1 FY26 and secured regulatory approval for its iTrack™ Advance device in China, setting the stage for expanded market penetration.
Ada Torres
31 Oct 2025

Nova Eye Medical Secures Key Approval to Expand Glaucoma Device Sales in China

Nova Eye Medical has gained regulatory approval for its iTrack Advance glaucoma device in China, setting the stage for significant market expansion and sales growth from late fiscal 2026.
Ada Torres
30 Sept 2025